Chan JK, et al. - Sunitinib was tested as a treatment option for recurrent or persistent clear cell ovarian cancer patients, with a focus on its efficacy and tolerability. Researchers administered sunitinib 50 mg per day for 4 weeks in repeated 6-week cycles until disease progression or toxicity was prohibitive. All patients in the study had one or two prior regimens with measurable disease, with tumors characterized by at least 50% clear cell histomorphology and negative for WT-1 antigen and estrogen receptor expression by immunohistochemistry. The study was intended to assess if the drug had a response rate of at least 20% or 6-month progression-free survival (PFS) of at least 25%. The reported median PFS and median overall survival were 2.7 months and 12.8 months, respectively. Overall, minimal activity was shown by sunitinib in the second- and third-line treatment of persistent or recurrent clear cell ovarian carcinoma.